文献速递炎症性肠病

早期干预预防溃疡性结肠炎疾病进展:多中心回顾性研究

Early Intervention Prevents Disease Progression in Ulcerative Colitis: A Multicenter Retrospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-02-27

多中心回顾性研究纳入236例成人溃疡性结肠炎患者,早期生物制剂治疗(确诊≤12个月)相比晚期启动可独立降低疾病进展 composite 终点风险(HR 4.39),并减少近端扩展和结肠结构损伤,但临床结局无差异。

要点

  • 晚期启动生物制剂独立预测UC疾病进展(HR 4.39)。
  • 早期生物制剂治疗与近端扩展风险降低相关(28.6% vs 0.0%)。
  • 晚期启动生物制剂独立预测结肠结构损伤(HR 4.83)。

核心结论

  • 在UC病程中早期启动生物制剂可能降低长期疾病进展风险,重塑机会窗口。

研究设计与样本

  • 多中心回顾性研究,纳入11个中心的成人UC患者,随访至少5年。
  • 早期干预定义为确诊后≤12个月内启动生物制剂治疗。

主要发现

  • 共纳入236例患者,28.8%(n=68)接受早期生物制剂治疗,中位随访6.9年(IQR 5.8-8.8年)。
  • 晚期启动生物制剂独立预测复合进展终点(23.2% vs 5.9%;HR 4.39;95%CI 1.57-12.29;P=.005)。
  • 早期生物制剂治疗与近端扩展风险降低相关(28.6% vs 0.0%;P=.001)。
  • 临床结局(住院、手术、皮质类固醇使用)无差异。

临床怎么用

  • 对于UC患者,考虑在确诊后12个月内启动生物制剂以降低疾病进展风险。

局限性

  • 回顾性研究设计可能引入选择偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Ulcerative colitis (UC) has increasingly been recognized as a progressive disease. However, unlike Crohn's disease, evidence in UC has not demonstrated a clear benefit of early biologic therapy (BT), and disease progression has not been formally evaluated. We aimed to assess whether early intervention improves UC outcomes, particularly in preventing disease progression. METHODS: We conducted a retrospective multicenter study (11 centers) including adult patients with UC with at least 5 years of follow-up. Early intervention was defined as BT initiation within ≤12 months of diagnosis. The primary outcome was UC progression, defined as a composite endpoint including proximal disease extension, colonic structural changes (stenosis or tubularization), and dysplasia/cancer. Secondary outcomes included clinical endpoints: hospitalizations, surgery, and corticosteroid use. RESULTS: A total of 236 patients were included, 28.8% (n = 68) with early BT (median follow-up, 6.9 years; interquartile range, 5.8-8.8 years). Late BT initiation (23.2% vs 5.9%) independently predicted the composite outcome of progression (hazard ratio, 4.39; 95% confidence interval, 1.57-12.29; P = .005). Assessing each outcome separately, early BT was associated with a reduced risk of proximal extension (28.6% vs 0.0%; P = .001). In multivariable Cox regression, late BT initiation (13.1% vs 2,9%) was an independent predictor of colonic structural damage (hazard ratio, 4.83; 95% confidence interval, 1.14-20.58; P = .033). No differences in clinical outcomes were observed. CONCLUSIONS: Starting BT early in the disease course may reduce the long-term risk of disease progression, reshaping the window of opportunity in UC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Camões Neves J, Leal T, Fernandes S, et al. Early Intervention Prevents Disease Progression in Ulcerative Colitis: A Multicenter Retrospective Study. Clin Gastroenterol Hepatol. 2026. PMID: 41763461. doi:10.1016/j.cgh.2026.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。